EBR Systems, Inc. (ASX:EBR): How WiSE Commercialisation and Funding Are Progressing

Aditi Sarkar

30 October 2026 03:52 PM AEDT

EBR Systems, Inc. (ASX:EBR): How WiSE Commercialisation and Funding Are Progressing

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

WiSE commercial implants reached 40 during Q3 2026, compared with 46 in Q2.
Preliminary Q3 revenue was estimated at US$2.43M to US$2.53M.
The final tranche of an A$150 million capital raising closed in August.
An expanded manufacturing facility received ISO 13485 certification.
Commercial execution, regulatory processes and liquidity remain important factors.

EBR Systems, Inc. (ASX:EBR) develops the WiSE System, a wireless device that delivers left ventricular endocardial pacing for cardiac resynchronisation therapy. During 2026, the company has been expanding its United States commercial operations while investing in manufacturing capacity, refining its hospital engagement approach and raising capital to support these activities.

Commercial Rollout and Implant Activity

In its 12 October 2026 commercial update, EBR Systems, Inc. (ASX:EBR) reported 40 commercial WiSE implants for the September quarter, compared with 46 in the June quarter. The cumulative number of implants across its pilot phase and limited market release reached 157. September activity was below the company’s earlier expectations.

Management attributed the lower procedure volume partly to a commercial leadership transition, changes in execution priorities and additional training requirements for the field team. The revised approach places greater emphasis on increasing use of WiSE at existing hospital accounts rather than opening numerous new accounts before utilisation becomes established.

EBR Systems, Inc. (ASX:EBR) estimated preliminary and unaudited Q3 2026 revenue of US$2.43M to US$2.53M, against Q2 revenue of approximately US$2.6M. The estimate remained subject to quarter-end adjustments.

Quarterly Financial Position and Capital Raising

For the June 2026 quarter, EBR Systems, Inc. (ASX:EBR) reported net sales of US$2,637 thousand and a net loss of US$17,453 thousand. Net sales for the six months ended 30 June 2026 were US$4,999 thousand, with a net loss of US$34,527 thousand. Cash used in operating activities over that six-month period totalled US$37,445 thousand.

At 30 June 2026, cash and cash equivalents stood at US$59,350 thousand, while cash and marketable securities together totalled US$86,943 thousand. The company’s June-quarter filing raised substantial doubt about its ability to continue as a going concern for at least twelve months, citing debt obligations and liquidity requirements.

In June, EBR Systems, Inc. (ASX:EBR) outlined an A$150 million capital raising comprising an institutional placement and an entitlement offer. The company confirmed in October that the final tranche had closed in August. Its stated funding purpose included commercialisation, sales-force development and manufacturing expansion. Proceeds from financing must be distinguished from cash generated through sales.

Manufacturing, Regulation and Near-Term Priorities

EBR Systems, Inc. (ASX:EBR) said the new Santa Clara manufacturing facility obtained ISO 13485 certification during Q3 2026. The US Food and Drug Administration completed a pre-approval inspection and issued two observations, which the company said it would address. The agency’s final determination on the facility approval remained outstanding at the time of the October update.

The company also reported regulatory engagement concerning echo-induced pacing risk and a cybersecurity incident. It stated that the FDA considered no immediate field corrective action or recall necessary for the cybersecurity issue. Separately, EBR filed an Australian application for registration of the WiSE System on 20 October 2026; an application is not equivalent to market approval.

Management identified further field training, hospital procedure frequency and the transition to the expanded facility as current priorities. Each depends on implementation and, where relevant, regulatory decisions. The lower Q3 implant count illustrates why the rate of commercial adoption cannot be inferred solely from manufacturing capacity or newly secured funding.

Key Insights

EBR Systems, Inc. (ASX:EBR) is balancing the costs of commercialising a specialist cardiac device against an evolving revenue base. Its 2026 disclosures combine growing operational infrastructure with a sequential decline in reported quarterly implant activity and material financing requirements. Subsequent results will clarify whether revised commercial execution, access to manufacturing capacity and available liquidity support sustained activity.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.